Vevzuo is authorized for the prevention of skeletal related events in adults with advanced malignancies involving bone
Approval based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the Imfinzi regimen vs. neoadjuvant chemotherapy alone
The study showed that sClever-1 is released by macrophages and blood vessel cells and binds to activated T cells
ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept
Opaganib has shown potential in enhancing ARPI treatment by blocking multiple enzymes involved in cancer cell survival.
The acquisition of Pivya is an important step in Alembic’s ability to provide branded pharmaceutical product to the US Healthcare market
ART-123 is a recombinant human thrombomodulin approved in Japan in 2008
InnoCell is the brand name for Mitsui Chemicals’ cell culture products and services
Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy
Subscribe To Our Newsletter & Stay Updated
